Nacka, Stockholm: - Pharmadule Morimatsu has been awarded the contract for design, fabrication, site installation and start-up of a state-of-the-art modular biomanufacturing plant in the US. The basic design was completed earlier this year and delivery and completion is scheduled for 2019. The owner will leverage the off-site fabrication of modular construction and complete site work in parallel to optimize the overall schedule and begin qualification and production activities much earlier than can be achieved with conventional stick-built construction. This will allow the owner to more quickly gain a return on investment.
Pharmadule Morimatsu AB is the Swedish-based global leader in the delivery of modular facilities to the Life Sciences Industry. Utilizing multidisciplinary expertise, including Process and Facility Engineering, Pharmadule is able to provide turnkey solutions anywhere in the world quickly, efficiently and cost effectively.